IMA vs. OGI, TLSA, ENGN, CRGX, IMRX, HRTX, TRDA, ACIU, LYEL, and GNFT
Should you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Organigram Global (OGI), Tiziana Life Sciences (TLSA), enGene (ENGN), CARGO Therapeutics (CRGX), Immuneering (IMRX), Heron Therapeutics (HRTX), Entrada Therapeutics (TRDA), AC Immune (ACIU), Lyell Immunopharma (LYEL), and GENFIT (GNFT). These companies are all part of the "pharmaceutical products" industry.
ImageneBio vs. Its Competitors
Organigram Global (NASDAQ:OGI) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.
Organigram Global has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.
ImageneBio has a consensus target price of $35.50, suggesting a potential upside of 164.93%. Given ImageneBio's stronger consensus rating and higher possible upside, analysts plainly believe ImageneBio is more favorable than Organigram Global.
In the previous week, ImageneBio had 1 more articles in the media than Organigram Global. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Organigram Global. Organigram Global's average media sentiment score of 1.88 beat ImageneBio's score of 1.28 indicating that Organigram Global is being referred to more favorably in the media.
Organigram Global has higher revenue and earnings than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.
34.6% of Organigram Global shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 0.1% of Organigram Global shares are held by insiders. Comparatively, 5.9% of ImageneBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Organigram Global has a net margin of 2.86% compared to ImageneBio's net margin of 0.00%. Organigram Global's return on equity of -8.19% beat ImageneBio's return on equity.
Summary
Organigram Global beats ImageneBio on 9 of the 16 factors compared between the two stocks.
Get ImageneBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImageneBio Competitors List
Related Companies and Tools
This page (NASDAQ:IMA) was last updated on 9/1/2025 by MarketBeat.com Staff
Free IMA Stock Alerts